Literature DB >> 2535752

Initial interaction of herpes simplex virus with cells is binding to heparan sulfate.

D WuDunn1, P G Spear.   

Abstract

We have shown that cell surface heparan sulfate serves as the initial receptor for both serotypes of herpes simplex virus (HSV). We found that virions could bind to heparin, a related glycosaminoglycan, and that heparin blocked virus adsorption. Agents known to bind to cell surface heparan sulfate blocked viral adsorption and infection. Enzymatic digestion of cell surface heparan sulfate but not of dermatan sulfate or chondroitin sulfate concomitantly reduced the binding of virus to the cells and rendered the cells resistant to infection. Although cell surface heparan sulfate was required for infection by HSV types 1 and 2, the two serotypes may bind to heparan sulfate with different affinities or may recognize different structural features of heparan sulfate. Consistent with their broad host ranges, the two HSV serotypes use as primary receptors ubiquitous cell surface components known to participate in interactions with the extracellular matrix and with other cell surfaces.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535752      PMCID: PMC247656     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  INHIBITION OF HERPES VIRUS BY NATURAL AND SYNTHETIC ACID POLYSACCHARIDES.

Authors:  K K TAKEMOTO; P FABISCH
Journal:  Proc Soc Exp Biol Med       Date:  1964-05

2.  Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration.

Authors:  S L Highlander; W H Cai; S Person; M Levine; J C Glorioso
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

3.  Electron microscopy of herpes simplex virus. I. Entry.

Authors:  C Morgan; H M Rose; B Mednis
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

4.  Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells.

Authors:  P M Ejercito; E D Kieff; B Roizman
Journal:  J Gen Virol       Date:  1968-05       Impact factor: 3.891

5.  Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity.

Authors:  P J Desai; P A Schaffer; A C Minson
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

6.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Characterisation of a herpes simplex virus type 1 mutant which has a temperature-sensitive defect in penetration of cells and assembly of capsids.

Authors:  C Addison; F J Rixon; J W Palfreyman; M O'Hara; V G Preston
Journal:  Virology       Date:  1984-10-30       Impact factor: 3.616

8.  Inhibitory effect of heparin on herpes simplex virus.

Authors:  A J Nahmias; S Kibrick
Journal:  J Bacteriol       Date:  1964-05       Impact factor: 3.490

9.  Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.

Authors:  H Mitsuya; D J Looney; S Kuno; R Ueno; F Wong-Staal; S Broder
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

10.  A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.

Authors:  M W Ligas; D C Johnson
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

View more
  326 in total

1.  Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

Authors:  M I Vázquez; M Esteban
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.

Authors:  J C Whitbeck; S A Connolly; S H Willis; W Hou; C Krummenacher; M Ponce de Leon; H Lou; I Baribaud; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins.

Authors:  G Zhou; V Galvan; G Campadelli-Fiume; B Roizman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spread.

Authors:  D A Rauch; N Rodriguez; R J Roller
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety.

Authors:  M L Heil; A Albee; J H Strauss; R J Kuhn
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Effects of herpes simplex virus on structure and function of nectin-1/HveC.

Authors:  Claude Krummenacher; Isabelle Baribaud; James F Sanzo; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 9.  Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry.

Authors:  D Shukla; P G Spear
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 10.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.